Related Experiment Videos
[Studies on DNA methylation in transformed mouse liver cells]
Shi Yan Sheng Wu Xue Bao
|December 1, 1989
Summary
This study reveals that both DNA methylase activity and DNA methylation levels are reduced in H22a ascitic hepatoma cells and affected mouse liver. Antitumor drug treatments increased DNA methylase activity but not methylation levels in tumor cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Context:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Altered DNA methylation is implicated in cancer development and progression.
- Understanding DNA methylase activity and methylation levels in tumor cells is crucial for developing effective therapies.
Purpose:
- To investigate the activity of DNA methylase and the level of DNA methylation in normal mouse liver, H22a ascitic hepatoma-bearing mouse liver, and H22a ascitic hepatoma cells.
- To assess the impact of antitumor drug treatments on DNA methylase activity and DNA methylation levels in tumor cells.
Summary:
- DNA methylase activity and DNA methylation levels were measured using H3-methyl incorporation and High-Performance Liquid Chromatography (HP-LC).
- Both DNA methylase activity and DNA methylation levels were found to be lower in H22a ascitic hepatoma cells and affected liver compared to normal mouse liver.
- Antitumor drug treatments resulted in increased DNA methylase activity in tumor cells, but did not significantly alter the DNA methylation level.
Impact:
- This research provides insights into the epigenetic alterations in hepatocellular carcinoma.
- Findings suggest that while antitumor drugs can enhance DNA methylase activity, they may not restore DNA methylation levels in tumor cells.
- Further investigation is warranted to explore the therapeutic potential of targeting DNA methylation in HCC treatment.